Spots Global Cancer Trial Database for First Line Ovarian Cancer Treatment - Cohort Study
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: First Line Ovarian Cancer Treatment - Cohort Study
Official Title: Non Interventional Study Dealing With the Use of Bevacizumab (Avastin®) in Patients With Epithelial Ovarian Cancer, Fallopian Tube or Primary Peritoneal and Treated in First-line Therapy
Study ID: NCT01832415
Conditions
Interventions
Study Description
Brief Summary: The French cooperative group GINECO proposes to implement an observational study to describe a real situation, in daily practice tolerance and methods of administration of bevacizumab (Avastin ®)
Detailed Description: Population: Patients aged 18 years and older with an epithelial ovarian cancer, fallopian tube or primary peritoneal or witch it was decided to initiate a process comprising of Bevacizumab (Avastin ®) in first-line therapy
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Centre Paul Papin, Angers, , France
Clinique Tivoli, Bordeaux, , France
Institut Bergonié, Bordeaux, , France
Centre jean Perrin, Clermont Ferrand, , France
Centre Hospitalier Intercommunal, Fréjus, , France
institut Paoli Calmette, Marseille, , France
Clinique Valdegour, Nimes, , France
Centre Hospitalier Régional, Orléans, , France
Arcagy-Gineco, Paris, , France
Centre Hospitalier Lyon-sud, Pierre-Bénite, , France
Institut Jean Godinot, Reims, , France
Clinique Armoricaine de Radiologie, Saint Brieuc, , France
ICO René Gauducheau, St Herblain, , France
Hôpital Civil, Strasbourg, , France
Contact Details
Name: Dominique BERTON-RIGAUD, MD
Affiliation: ICO de l'Ouest, Site René Gauducheau - Saint-Herblain
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
